RxDoctor Payments Data

Anil Ananthaneni

Shreveport, LANPI 1154932994

Payments from drug & device makers

$3,255in general payments, 2019–2025

Across 106 payments — averaging $30.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$540
  • GSK$374
  • Daiichi Sankyo Inc.$362
  • AbbVie$266
  • AstraZeneca$220
  • Lilly USA, LLC$143
  • plus $1K from 27 others

What the payments were for

  • Speaking & faculty fees$1254%
  • Food & beverage$2,41474%
  • Education$41713%
  • Other$2999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abiraterone Acetate13$8,310
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$674
Morphine Sulfate ErMorphine Sulfate17$415
Dexamethasone13$267
Oxycodone Hcl15$258
Anastrozole11$252
Gabapentin11$82
Tamsulosin Hcl12$48
Prednisone12$47
Amlodipine Besylate13$29

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →